We assessed a large number of adults (368 from Australia and 494 from Japan) with de novo acute myeloid leukemia (AML) to define the biological differences between the two populations. In this study, AML was classified using the FrenchAmerican-British (FAB) criteria into seven groups (M1-M7). M2 was more common in Japan than in Australia, whereas M4 occurred more frequently in Australia than in Japan. Other FAB subtypes were evenly distributed. Cytogenetically, Japanese M2 displayed a higher frequency of t(8;21) than Australian (33.1% vs 15.3%, P Ͻ 0.05). The t(15;17), inv/del(16), 11q23 aberrations and 5/7/8 abnormalities were seen at similar frequencies. Immunophenotypically, Japanese M4/M5 more frequently displayed CD13 and CD14 than Australian, whereas the stem cell markers, CD34 and HLA-DR were observed at a relatively higher rate in Australian M3 than in Japanese M3. The B cell antigen, CD19 was more frequently seen in Japanese M2 than in Australian M2, but found more often in Australian M5 than in Japanese M5. In both populations, a close relationship was observed between the expression of CD19 and t(8;21). These findings suggest different biological characteristics of AML between the two populations, the main differences being generated by a higher frequency of t(8;21) chromosomal abnormality in Japanese AML. Leukemia (2000) 14, 163-168.
Introduction
It is known that there are some differences in the incidence and characteristics of lymphoid malignancies between Western countries and Japan. [1] [2] [3] Hodgkin's disease and certain B cell tumors such as follicular lymphoma and chronic lymphocytic leukemia are commonly seen in the West, but are rare in Japan. On the other hand, the relatively increased frequency of T cell neoplasms including adult T cell leukemia/lymphoma has been demonstrated in Japan. Among myeloid malignancies, acute myeloid leukemia (AML) in adults is also known to be a heterogenous disease with diverse morphologic, immunophenotypic, cytogenetic and clinical characteristics. 4, 5 However, little is known about the similarities and differences in the features of AML between these two populations. This could provide epidemiological clues for new research on the pathogenesis of AML.
In this study, we surveyed a large population of adult patients with newly diagnosed de novo AML from Australia and Japan, studying the morphology, immunophenotype and cytogenetics at diagnosis in relation to the age of patients to investigate whether these two populations have significant biological differences. 
Materials and methods

Patients
Three hundred and sixty-eight Australian and 494 Japanese adult patients (older than 15 years) with newly diagnosed untreated AML during the same period from 1986 to 1997 were studied. Australian patients were those referred to leukemia treatment units at seven large regional or tertiary referral hospitals in the Sydney Metropolitan or Newcastle areas and included a minority of Asian people (25 patients were Asian based on country of birth). Japanese patients were from two large hospitals in Osaka or Hiroshima Prefecture and from Mie University Hospital and its related hospitals in Mie Prefecture and from Fukui Medical College Hospital in Fukui Prefecture; all were Japanese. Morphological diagnosis was made according to the French-American-British (FAB) criteria for AML 6, 7 and cases were classified into one of seven AML subtypes as follows: M1, M2, M3, M4, M5, M6 and M7. Before comparing the FAB subtype, several hematologists in respective countries reviewed Giemsa-stained films of peripheral blood (PB) and bone marrow (BM) and available cytochemical stains (myeloperoxidase and non-specific esterase), and confirmed the coincidence of FAB subtyping between the two countries. We excluded FAB criteria undetermined cases and acute leukemia occurring after myelodysplastic syndrome and myeloproliferative disorders, or secondary AML occurring after treatment of other malignancies. Cases of myelodysplastic syndrome were excluded, according to published criteria, 8 but cases of frank de novo AML with accompanying dysplasia were not excluded.
Immunophenotyping
Mononuclear cells (MNC) were separated from heparinized PB and BM by Ficoll-Paque centrifugation. Before immunostaining, MNC were treated with heat-aggregated human AB serum to prevent non-specific binding of monoclonal antibodies (MoAbs) through Fc receptors. Cell surface antigens were detected by a standard indirect immunofluorescence method, as previously described, 9,10 using a panel of MoAbs as follows: CD11b (WM20/ OKM1), CD13 (WM15/ MCS2), CD14 (FMC33/My4), CD33 (WM53/My9) and CD41 (WM18/J15) as myeloid markers; CD2 (WM57/T11) and CD7 (WM31/Tp40) as T cell markers; CD10 (WM21/J5) and CD19 (FMC63,B4/ B4) as B cell markers; and HLA-DR (WM2/OKIa1) and CD34 (HPCA1/HPCA1) as stem cell markers (Australian use/Japanese use, respectively). Sheep anti-mouse Ig fluorescein-conjugates (SAM-FITC) and goat anti-mouse Ig fluorescein-conjugates (GAM-FITC) were used as the second reagent in the two countries, respectively. As negative controls, mouse IgG1 (WMD10), IgG2a (WMD6) and IgG2b
Leukemia (WMD7) were used in Australia and whole mouse Igs, IgG1 and IgG2 (Chemicon, Temecula, CA, USA) in Japan. MoAbs of the WM series were kindly provided by Westmead Hospital, Sydney, Australia; FMC series, Dr H Zola, Flinders Medical Centre, Adelaide, Australia; Tp40, Dr R Ueda, Aichi Cancer Center, Nagoya, Japan; MCS2, Dr E Tatsumi, Kobe University, Kobe, Japan. The Leu series were purchased from Becton Dickinson (Mountain View, CA, USA); the other MoAbs and GAM-FITC from Coulter (Hialeah, FL, USA); SAM-FITC from Silenus (Melbourne, Australia). Samples were examined by flow cytometry using instruments available at each institution.
Results were recorded on blast-gated populations. Positivity for each MoAb was uniformly defined in both countries as 20% or more of cells positive above the negative control. In the cases of suspected lymphoid lineage antigen expression (CD2, CD7, CD10 and CD19), the case was considered positive when the percentage of that marker plus the highest value for a myeloid marker or stem cell marker exceeded 110%.
Cytogenetic studies
Chromosome analysis of bone marrow cells was performed at diagnosis on short term (usually 24 h) BM cultures.
11 Metaphase chromosomes were banded by the conventional Giemsa banding technique and karyotyped according to the International System for Human Cytogenetic Nomenclature (ISCN) (1985)). We examined the expression of the following karyotypic abnormalities; t(8;21) (q22;q22), t(15;17) (q22;q11), inv/del(16) (q22), t/del(11)(q23), −5 or 5q−/−7 or 7q−/8+ and other abnormalities.
Statistical analysis
The statistical software package SPSS Version 7 (SPSS, Chicago, IL, USA) was used for all analyses. Multivariate logistic regression analysis 12 was used to test for differences in the age and sex distributions of Japanese and Australian patients. This type of analysis was also used to test for heterogeneity of the FAB subtype, chromosomal abnormalities, and myelomonocytic, stem cell and lymphoid antigen expression in patients from the two countries. The analyses were age adjusted where necessary. No significant interactions with age were identified.
The relationship between country, FAB subtype and antigen expression was investigated by fitting a logistic regression model with country as the dependent variable and FAB subtype, antigen expression and age together with their first order interactions as independent variables. Since significant interactions were detected between FAB subtype and each of CD13, CD14, HLA-DR and CD19, it was decided to model the relationship between country and antigen expression separately for each FAB subtype. Neither age nor any of its first order interactions with antigen expression were statistically significant in these models. Therefore the odds ratios have been expressed unadjusted for age.
Results
Patients characteristics and FAB subtype
There were no significant differences of age and sex distribution between Australian patients and Japanese patients (Table 1 ). The frequency of FAB morphological subtype in the two countries is shown in Table 2 . There was a statistically significant difference in the FAB subtype distribution between Japan and Australia (X 2 = 33, df = 6, P Ͻ 0.001). M2 was more prominent and M4 and M7 less prominent in Japanese patients. The age-adjusted odds ratios associated with each of these subtypes compared to M1 were respectively 1.7 (95% CI 1.1-2.5), 0.67 (95% CI 0.43-1.0) and 0.12 (95% CI 0.01-1.0). No significant differences were observed in other subtypes.
Cytogenetics
Cytogenetics data was available on 230 patients from Australia and 438 from Japan. The higher rate of cytogenetic results in Japanese patients probably reflects better referral of bone marrow diagnostic samples from a smaller number of Japanese centers than the more geographically dispersed Australia centers. The incidence of chromosomal abnormalities was compared between the two countries (Table 3 ). There was a statistically significant difference in the distribution of chromosomal abnormalities between Japan and Australia (X 2 = 24, df = 6, P = 0.001). Translocation t(8;21) was more prominent and abnormalities of chromosomes 5, 7 and 8 less prominent in Japanese patients. The age-adjusted odds ratios associated with each of these abnormalities compared to normal were respectively 2.9 (95% CI 1.5-5.7) and 0.53 (95% CI 0.31-0.91). Other chromosomal abnormalities were found at similar frequencies in the two populations.
With regard to the relationship between particular chromosomal aberrations and FAB subtype (Table 4) , the frequency of t(8;21) was higher in M2 in Japanese patients than in Australian (33.1% vs 15.3%, P Ͻ 0.05). Among such Australian patients, two were of genuine Asian origin. The t(15;17) occurred in M3 in both populations with approximately similar frequency.
Immunophenotype
The results of immunophenotyping of AML patients from both countries in relation to the FAB subtype is indicated in Table  5 and 6. There was a statistically significant interaction between the FAB subtype and the expression of several myelomonocytic and stem cell antigens (namely CD13, CD14, HLA-DR and CD19) amongst Japanese and Australian patients. Therefore the relationship between country and antigen expression was investigated separately for each FAB subtype. No adjustment for age was required. Only subtypes M1-5 are shown as there were too few M6 and M7 for meaningful analysis. For the M1 and M2 subtypes, the antigen expression rates were comparable in Japanese and Australians. For the M3 subtype CD34 and HLA-DR expression was less common in the Japanese, the respective odds ratios being 0.40 (95% CI 0.13-1.2) and 0.23 (95% CI 0.06-0.94). Note that these ratios are relative to M3 subtypes not expressing the antigen of interest. For the M4 subtype CD14 expression was significantly more common in the Japanese (OR 8.3 (95% CI 3.5-19.8)). For the M5 subtype CD13 expression was significantly more common in the Japanese (OR 4.3 (95% CI 1.6-11.4)).
There was also a significant interaction between the FAB subtype and the expression of lymphoid antigens which were therefore analyzed separately by subtypes. For the M3 and M4 subtypes, the antigen expression rates were comparable in Japanese and Australians. For the M1 and M2 subtypes CD19 expression was significantly more common in the Japanese, the respective odds ratios being 3.3 (95% CI 1.1-10.3) and 5.1 (95% CI 1.7-14.8) for those expressing CD19 compared to those who do not within each subtype. For the M5 subtype CD19 expression was significantly less common in the Japanese (OR 0.07 (95% CI 0.007-0.60)).
Leukemia
Relationship between t(8;21) and CD19
It has been previously reported that there is a statistically significant association between the presence of the t(8;21) abnormality and the expression of CD19. 13, 14 We therefore decided a priori to investigate this relationship in particular in our study. The association of t(8:21) and CD19 was confirmed, independent of country ( Table 7 ). The odds of CD19 expression were 38 times higher (95% CI 20-72) amongst those with t(8;21) than amongst those without this abnormality.
Discussion
Acute myeloid leukemia is a heterogenous group of diseases which includes several discrete syndromes with characteristic clinical, morphological, phenotypic and cytogenetic features. 4, 5 The chromosomal abnormalities, best exemplified by the t(15;17) in FAB M3 disease, 15, 16 result in unique molecular rearrangements, which provide insights into the pathogenesis of each of these disease syndromes, and could potentially define etiological factors involved in leukemogenesis. More precise delineation of the subtypes of AML occurring in different human populations may allow a better understanding of the genetic and environmental factors involved in their genesis. For this reason, we studied the laboratory features of AML cases occurring in the contrasting societies of Japan and Australia. The Japanese cases occurred within an ethnically hom- ogenous Asian population residing in a predominantly urban industralized area of Japan. The Australian cases were collected from two large cities on the eastern coast of New South Wales. Although the Australian population is now quite ethnically diverse, including a significant minority of people of Asian origin, the majority are of Caucasoid origin from northern and southern Europe, and therefore represent an ethnically different population as compared to Japan. The major finding of this study was an increased frequency of cases of FAB M2 AML, associated with the t(8;21) chromosomal abnormality, in Japanese as compared to Australians. The observed increased frequency of M2 cases in Japanese patients was almost entirely explained by the increased number of cases of t(8;21) AML, with 33.1% of M2 cases having this cytogenetic marker in Japan as compared to only 15.3% of Australian patients. Previous surveys of cytogenetic changes in AML have suggested a high frequency of t(8;21) abnormality in Asian populations, although with widely variable results. The range of reported incidence of t(8;21) in FAB M2 subtype was 58-88% of Asian cases, 17, 18 19-54% in Europe, 18 and 12-27% in the USA. 18, 19 The results of our direct comparison of an Asian and a Western society confirm the above data. FAB subtypes M4 and M7 were relatively more common in Australian patients, and there was a slightly higher frequency of abnormalities of chromosomes 5, 7 and 8 in Australians. No differences were observed between the two populations in the frequency of other specific chromosomal markers.
We also observed a correlation between the CD19 antigen, M2 subtype, and the t(8;21) abnormality, with more than 50% of t(8;21) cases expressing CD19 in both Japanese and Australian patients. This finding is consistent with previously published reports, 13, 14 and strengthens the reliability of CD19 as a marker of t(8;21) AML. In Australia, however, CD19 was also frequently detected in M5 AML, which is in agreement with the data described in other Western countries. 20, 21 Other lymphoid markers were observed at expected frequencies on AML subtypes, [22] [23] [24] [25] [26] and no statistically significant differences were seen between the two populations. The myelomonocytic markers showing significant differences in frequency of expression were CD14, which was detected more frequently in Japanese M4 cases as compared to Australian, and CD13, which was found more often in Japanese than Australian M5 cases. In contrast although the stem cell markers CD34 and HLA-DR are uncommonly found in M3 subtype, Australian cases showed a relatively higher rate of their expression compared to Japanese cases. The reason for these discrepancies is not completely clear, but may relate to different cellular characteristics between the two populations or the different antibodies used. [27] [28] [29] The different incidences of t(8;21) AML in Japanese and Australian societies strongly suggests a genetic susceptibility to this chromosomal change in Japanese people, or an environmental factor, or both. The t(8;21) abnormality is highly correlated with the FAB M2 subtype, 4, 13, 14 and results in a distinct molecular rearrangement involving two nuclear transcription factors ETO on chromosome 8q22 and AML-1 on chromosome 21q22. [30] [31] [32] Rearrangements involving the AML-1 gene are the most common abnormality in acute leukemia, including the t(8;21) and t(3;21) in AML, 33 as well as t(12;21) in pediatric ALL. 34 In addition, the inversion 16 abnormality in the M4Eo variant of AML involves core binding factor-2, which forms part of the transcription complex with AML-1. 35 In summary, our results show that a higher frequency of the chromosomal abnormality t (8;21) in Japanese compared to Australian adults with AML generates the main differences in morphology and immunophenotype in AML cases in these Asian and Western societies. Further research is required to identify the genetic or environmental factors responsible for this increased incidence of t(8;21) in Japanese AML patients.
